Sonnet BioTherapeutics Holdings, Inc. Announces Stockholder Approval of Proposed Business Combination with Hyperliquid Strategies Inc

Group 1 - Sonnet BioTherapeutics Holdings, Inc. announced that its stockholders approved the proposed business combination with Hyperliquid Strategies Inc and Rorschach I LLC at a special meeting [1] - The final voting results for the special meeting will be filed in a Form 8-K with the U.S. Securities and Exchange Commission [1] Group 2 - Sonnet BioTherapeutics is an oncology-focused biotechnology company that utilizes a proprietary platform known as FHAB (Fully Human Albumin Binding) for developing biologic drugs [2] - The FHAB technology employs a fully human single chain antibody fragment that binds to human serum albumin for targeted transport to tumor and lymphatic tissues, enhancing the safety and efficacy of immune modulating biologic drugs [2] - FHAB serves as a modular construct for various large molecule therapeutic classes, including cytokines, peptides, antibodies, and vaccines [2]